Gregory S. Moss Esq. serves as Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary of the Company. Mr. Moss also serves as Kadmon’s Chief Compliance Officer. Mr. Moss joined Kadmon in 2012 and from 2015 until August 2019, served as our Senior Vice President, Deputy General Counsel. Prior to joining the Company, Mr. Moss worked as a solicitor in the Corporate Risk practice group of one of Australia’s leading law firms and at a boutique legal practice and hedge fund in New York City.
As the Executive Vice President, Chief Compliance Officer, General Counsel, e Corporate Secretary of Kadmon Inc, the total compensation of Gregory Moss at Kadmon Inc is $1,046,570. There are 2 executives at Kadmon Inc getting paid more, with Harlan Waksal having the highest compensation of $4,742,770.
Gregory Moss is 36, he's been the Executive Vice President, Chief Compliance Officer, General Counsel, e Corporate Secretary of Kadmon Inc since 2019. There are 9 older and no younger executives at Kadmon Inc. The oldest executive at Kadmon Holdings Inc is Eugene Bauer, 77, who is the Independent Director.
Gregory's mailing address filed with the SEC is C/O KADMON HOLDINGS, INC., 450 E. 29TH STREET, NEW YORK, NY, 10016.
Over the last 8 years, insiders at Kadmon Inc have traded over $7,020,661 worth of Kadmon Inc stock and bought 7,084,916 units worth $54,943,934 . The most active insiders traders include Advisors Llcperceptive Life..., Asset Management Lp Golden ..., eDaniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,948,175. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth $46,880.
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
Kadmon Inc executives and other stock owners filed with the SEC include: